Publications by authors named "David Apelian"

Claim this Profile
A
A phase 2 dose-finding study of lonafarnib and ritonavir with or without interferon alpha for chronic delta hepatitis.
Cihan Yurdaydin, Onur Keskin, Esra Yurdcu, Aysun Çalişkan, Soner Önem, David Apelian

Hepatology· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase 2 Randomized Placebo-Controlled Adjuvant Trial of GI-4000, a Recombinant Yeast Expressing Mutated RAS Proteins in Patients with Resected Pancreas Cancer.
Peter Muscarella, Tanios Bekaii-Saab, Kristi McIntyre, Alexander Rosemurgy, Sharona B Ross, David Apelian

J Pancreat Cancer· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics, safety, and tolerability of the 2- and 3-direct-acting antiviral combination of AL-335, odalasvir, and simeprevir in healthy subjects.
Thomas N Kakuda, Matthew W McClure, Christopher Westland, Jennifer Vuong, Marie-Claude Homery, David Apelian

Pharmacol Res Perspect· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
Whole Recombinant Saccharomyces cerevisiae Yeast Expressing Ras Mutations as Treatment for Patients With Solid Tumors Bearing Ras Mutations: Results From a Phase 1 Trial.
Allen Cohn, Michael A Morse, Bert O'Neil, Samuel Whiting, Claire Coeshott, David Apelian

J Immunother· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A whole recombinant yeast-based therapeutic vaccine elicits HBV X, S and Core specific T cells in mice and activates human T cells recognizing epitopes linked to viral clearance.
Thomas H King, Charles B Kemmler, Zhimin Guo, Derrick Mann, Yingnian Lu, David Apelian

PLoS One· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II study of the GI-4000 KRAS vaccine after curative therapy in patients with stage I-III lung adenocarcinoma harboring a KRAS G12C, G12D, or G12V mutation.
Jamie E Chaft, Anya Litvak, Maria E Arcila, Payal Patel, Sandra P D'Angelo, David M Apelian

Clin Lung Cancer· November 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, tolerability and immunogenicity of GS-4774, a hepatitis B virus-specific therapeutic vaccine, in healthy subjects: a randomized study.
Anuj Gaggar, Claire Coeshott, David Apelian, Timothy Rodell, Brian R Armstrong

Vaccine· September 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I trial of a recombinant yeast-CEA vaccine (GI-6207) in adults with metastatic CEA-expressing carcinoma.
Marijo Bilusic, Christopher R Heery, Philip M Arlen, Myrna Rauckhorst, David Apelian

Cancer Immunol Immunother· March 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combination therapy with a second-generation androgen receptor antagonist and a metastasis vaccine improves survival in a spontaneous prostate cancer model.
Andressa Ardiani, Benedetto Farsaci, Connie J Rogers, Andy Protter, Zhimin Guo, David Apelian

Clin Cancer Res· November 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunological targeting of tumor cells undergoing an epithelial-mesenchymal transition via a recombinant brachyury-yeast vaccine.
Duane H Hamilton, Mary T Litzinger, Alessandra Jales, Bruce Huang, Romaine I Fernando, David Apelian

Oncotarget· October 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exploitation of differential homeostatic proliferation of T-cell subsets following chemotherapy to enhance the efficacy of vaccine-mediated antitumor responses.
Sofia R Gameiro, Jorge A Caballero, Jack P Higgins, David Apelian, James W Hodge

Cancer Immunol Immunother· September 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Maturation of human dendritic cells with Saccharomyces cerevisiae (yeast) reduces the number and function of regulatory T cells and enhances the ratio of antigen-specific effectors to regulatory T cells.
Vittore Cereda, Matteo Vergati, Ngar-Yee Huen, Maria Giovanna di Bari, Caroline Jochems, David Apelian

Vaccine· July 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mutation-specific control of BCR-ABL T315I positive leukemia with a recombinant yeast-based therapeutic vaccine in a murine model.
Melanie R Bui, Victoria Hodson, Tom King, Derek Leopold, Shaodong Dai, David Apelian

Vaccine· August 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
Whole recombinant yeast-based immunotherapy induces potent T cell responses targeting HCV NS3 and Core proteins.
Aurelia A Haller, Georg M Lauer, Thomas H King, Charles Kemmler, Valerie Fiolkoski, David Apelian

Vaccine· February 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B.
Ting-Tsung Chang, Robert G Gish, Robert de Man, Adrian Gadano, José Sollano, David Apelian

N Engl J Med· March 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis